Zydus' Humira Biosimilar: The Story So Far In India

One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.